Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exelixis (EXEL)
NASDAQ:EXEL
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.38Last Year’s EPS
0.12Same Quarter Last Year
Moderate Buy
Based on 20 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 11, 2025
|% Change Since: 6.95%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Exelixis with strong growth in its cabozantinib franchise, significant regulatory and pipeline advancements, and a robust financial position. While there are challenges with increased operating expenses and gross to net deductions, the overall trajectory indicates momentum and growth opportunities.Company Guidance
During the Exelixis Fourth Quarter and Fiscal Year 2024 Financial Results Conference Call, the company provided robust financial metrics and strategic guidance for 2025. Exelixis reported fourth-quarter 2024 total revenues of approximately $567 million, including $515.2 million from the cabozantinib franchise. In the full year 2024, U.S. cabozantinib franchise net product revenues grew 11% to $1.81 billion. The company outlined its ambitious revenue goals for its key oncology products, targeting $3 billion for cabozantinib by 2030 and $5 billion for zanzalintinib by 2033. Looking ahead to 2025, Exelixis plans to advance its cabozantinib NET indication, with a PDUFA date set for April 3, 2025, and aims to spotlight zanzalintinib as a major oncology franchise opportunity, with several pivotal trial readouts expected in the second half of the year. The company also highlighted its strong balance sheet, with cash and marketable securities totaling approximately $1.75 billion, and its continued commitment to capital allocation through share repurchases and strategic business development to bolster its pipeline.Strong Performance of Cabozantinib Franchise
The cabozantinib business saw an approximate 11% growth in demand, new starts, and revenue. Fourth quarter U.S. cabo franchise net product revenues grew 20% year-over-year to $515 million, while full year 2024 U.S. cabo franchise net product revenues grew 11% to $1.81 billion.
Regulatory Progress for Cabozantinib
The FDA accepted the sNDA for cabozantinib in pNET and epNET indications with a PDUFA date of April 3, 2025. Detailed final results from the CABINET Phase III pivotal trial were published in the New England Journal of Medicine.
Pipeline Growth and New Trials
Exelixis plans to accelerate the Phase I development of XL309 and file up to three new INDs for XB628, XB064, and XB371 in 2025, with significant data presentations expected at major scientific meetings.
Strong Financial Position
The company reported a GAAP net income of approximately $139.9 million for the fourth quarter and repurchased approximately $656 million of the company's shares in 2024.
---
EXEL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
EXEL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 11, 2025 | $32.81 | $32.80 | -0.03% |
| Oct 29, 2024 | $28.73 | $32.44 | +12.91% |
| Aug 06, 2024 | $23.45 | $26.52 | +13.09% |
| Apr 30, 2024 | $23.46 | $21.92 | -6.56% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Exelixis (EXEL) report earnings?
Exelixis (EXEL) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Exelixis (EXEL) earnings time?
Exelixis (EXEL) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EXEL EPS forecast?
EXEL EPS forecast for the fiscal quarter 2025 (Q1) is 0.38.
---